Person getting a vaccine
FILE – In this March 16, 2020, file photo, Neal Browning receives a shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. The vaccine by Cambridge, Massachusetts-based Moderna Inc., generated antibodies similar to those seen in people who have recovered from COVID-19 in a study of volunteers who were given either a low or medium dose. (AP Photo/Ted S. Warren, File)

 

By MARILYNN MARCHIONE AP Chief Medical Writer

An experimental vaccine against the coronavirus showed encouraging results in very early testing, triggering hoped-for immune responses in eight healthy, middle-aged volunteers, its maker announced Monday.

Study volunteers given either a low or medium dose of the vaccine by Cambridge, Massachusetts-based Moderna Inc. had antibodies similar to those seen in people who have recovered from COVID-19.

In the next phase of the study, led by the U.S. National Institutes of Health, researchers will try to determine which dose is best for a definitive experiment that they aim to start in July.

In all, 45 people have received one or two shots of the vaccine, which was being tested at three different doses. The kind of detailed antibody results needed to assess responses are only available on eight volunteers so far.

The vaccine seems safe, the company said, but much more extensive testing is needed to see if it remains so. A high dose version is being dropped after spurring some short-term side effects.

The results have not been published and are only from the first of three stages of testing that vaccines and drugs normally undergo. U.S. government officials have launched a project called “Operation Warp Speed” to develop a vaccine and hopefully have 300 million doses by January.

Worldwide, about a dozen vaccine candidates are in the first stages of testing or nearing it. Health officials have said that if all goes well, studies of a potential vaccine might wrap up by very late this year or early next year.

More than 4.7 million infections and 315,000 deaths from the coronavirus have been confirmed worldwide since it emerged in China late last year. There are no specific approved treatments, although several are being used on an emergency basis after showing some promise in preliminary testing.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

 

Contact mOppenheimTV

video-banner-fpo
Thank you for your interest in mOppenheimTV. Do you have a question or comment about our programs or services? Please get in touch with us! We welcome any feedback you may have.

Your Name (required)

Your Organization (required)

Your Email (required)

Your Phone (required)

Subject (required) - check any that apply
INSIGHTNonprofit SpotlightPBS CollaborationExecutive SearchOther

Your Message

To submit, please enter the characters below into the bottom field:
[recaptcha class:mtv-recaptcha]

Moderna: Early Coronavirus Vaccine Results Are Encouraging

AP, COVID-19, Health, News |